{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T18:38:12Z","timestamp":1768243092267,"version":"3.49.0"},"reference-count":137,"publisher":"Bentham Science Publishers Ltd.","issue":"7","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant No. 82404747"],"award-info":[{"award-number":["Grant No. 82404747"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Program for Excellent Sci-tech Innovation Teams of Universities in Anhui Province, China","award":["Grant No. 2023AH010073"],"award-info":[{"award-number":["Grant No. 2023AH010073"]}]},{"name":"Doctoral Scientific Research Startup Foundation of Wannan Medical College, Wuhu, China","award":["Grant No. WYRCQD2023005"],"award-info":[{"award-number":["Grant No. WYRCQD2023005"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Physiologically based pharmacokinetic (PBPK) modeling is a computational technique that uses\nthe physicochemical properties of drugs and physiological information to simulate plasma and tissue concentrations.\nPBPK modeling has become a mainstream approach in drug research and development, frequently\nemployed to support regulatory packages for new drug applications. Understanding the pharmacokinetic characteristics\nof anti-HIV drugs is essential for successful treatment. In recent decades, PBPK modeling has been\ncommonly used in the development and clinical therapy of anti-HIV medications. This review discusses the\nprevalence and application of PBPK modeling in the pharmacokinetics of anti-HIV drugs. Among the articles\nretrieved for this review, PBPK modeling was predominantly employed for anti-HIV drugs in contexts, such\nas pregnancy, drug\u2013drug interactions, and pediatrics. The most commonly used software programs for this\nmodel are Simcyp, MATLAB, and PK-sim. This review will provide insights for researchers in applying\nPBPK models to manage patients with HIV infection, aiming to enhance the efficacy of anti-HIV drug therapy\nand prevent undesirable adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892002392579250902053006","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T04:04:31Z","timestamp":1758254671000},"page":"472-488","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Application of Physiologically Based Pharmacokinetic Modeling in the Research of Anti-HIV Drugs"],"prefix":"10.2174","volume":"26","author":[{"given":"Yuewu","family":"Xie","sequence":"first","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huilong","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengpeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaozhen","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Han","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Wannan Medical College, Wuhu, China"},{"name":"Anhui College of Traditional Chinese Medicine, Wuhu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"29895","DOI":"10.1038\/s41598-024-81510-y","volume":"14","author":"Ogutu S.","year":"2024","unstructured":"Ogutu S.; Mohammed M.; Mwambi H.; Cytokine profiles as predictors of HIV incidence using machine learning survival models and statistical interpretable techniques. Sci Rep  2024,14(1),29895","journal-title":"Sci Rep"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1518314","DOI":"10.3389\/fpubh.2024.1518314","volume":"12","author":"Abebe M.","year":"2025","unstructured":"Abebe M.; Asgedom Y.S.; Gebrekidan A.Y.; Wondimagegne Y.A.; Hareru H.E.; Tebeje T.M.; Factors associated with HIV testing among young women in Tanzania: Insights from the 2022 tanzanian demographic and health survey using anderson\u2019s behavioral model. Front Public Health  2025,12,1518314","journal-title":"Front Public Health"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.tips.2021.10.004","volume":"43","author":"Men\u00e9ndez-Arias L.","year":"2022","unstructured":"Men\u00e9ndez-Arias L.; Delgado R.; Update and latest advances in antiretroviral therapy. Trends Pharmacol Sci  2022,43(1),16-29","journal-title":"Trends Pharmacol Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/17425255.2020.1814737","volume":"16","author":"Desai N.","year":"2020","unstructured":"Desai N.; Burns L.; Gong Y.; Zhi K.; Kumar A.; Summers N.; Kumar S.; Cory T.J.; An update on drug\u2013drug interactions between antiretroviral therapies and drugs of abuse in HIV systems. Expert Opin Drug Metab Toxicol  2020,16(11),1005-1018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","volume":"5","author":"Hamers R.L.","year":"2018","unstructured":"Hamers R.L.; Rinke de Wit T.F.; Holmes C.B.; HIV drug resistance in low-income and middle-income countries. Lancet HIV  2018,5(10),e588-e596","journal-title":"Lancet HIV"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/jcph.2025","volume":"62","author":"Cottura N.","year":"2022","unstructured":"Cottura N.; Kinvig H.; Gra\u00f1ana-Castillo S.; Wood A.; Siccardi M.; Drug-drug interactions in people living with HIV at risk of hepatic and renal impairment: Current status and future perspectives. J Clin Pharmacol  2022,62(7),835-846","journal-title":"J Clin Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/cpt.1393","volume":"105","author":"Devanathan A.S.","year":"2019","unstructured":"Devanathan A.S.; Anderson D.J.C.; Cottrell M.L.; Burgunder E.M.; Saunders A.C.; Kashuba A.D.M.; Contemporary drug-drug interactions in HIV treatment. Clin Pharmacol Ther  2019,105(6),1362-1377","journal-title":"Clin Pharmacol Ther"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/COH.0000000000000701","volume":"16","author":"Nhean S.","year":"2021","unstructured":"Nhean S.; Tseng A.; Back D.; The intersection of drug interactions and adverse reactions in contemporary antiretroviral therapy. Curr Opin HIV AIDS  2021,16(6),292-302","journal-title":"Curr Opin HIV AIDS"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/cpt.2192","volume":"109","author":"Hazenberg P.","year":"2021","unstructured":"Hazenberg P.; Navaratnam K.; Busuulwa P.; Waitt C.; Anti-infective dosing in special populations: Pregnancy. Clin Pharmacol Ther  2021,109(4),977-986","journal-title":"Clin Pharmacol Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cpt.3289","volume":"116","author":"Rowland Yeo K.","year":"2024","unstructured":"Rowland Yeo K.; Gil Berglund E.; Chen Y.; Dose optimization informed by PBPK modeling: State-of-the art and future. Clin Pharmacol Ther  2024,116(3),563-576","journal-title":"Clin Pharmacol Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1517\/17425255.2015.1037278","volume":"11","author":"Moss D.M.","year":"2015","unstructured":"Moss D.M.; Marzolini C.; Rajoli R.K.R.; Siccardi M.; Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. Expert Opin Drug Metab Toxicol  2015,11(8),1203-1217","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3390\/vaccines12070782","volume":"12","author":"Costa B.","year":"2024","unstructured":"Costa B.; Gouveia M.J.; Vale N.; Safety and efficacy of antiviral drugs and vaccines in pregnant women: Insights from physiologically based pharmacokinetic modeling and integration of viral infection dynamics. Vaccines  2024,12(7),782","journal-title":"Vaccines"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1208\/s12248-020-00508-2","volume":"22","author":"Riedmaier A.E.","year":"2020","unstructured":"Riedmaier A.E.; DeMent K.; Huckle J.; Bransford P.; Stillhart C.; Lloyd R.; Alluri R.; Basu S.; Chen Y.; Dhamankar V.; Dodd S.; Kulkarni P.; Olivares-Morales A.; Peng C.C.; Pepin X.; Ren X.; Tran T.; Tistaert C.; Heimbach T.; Kesisoglou F.; Wagner C.; Parrott N.; Use of physiologically based pharmacokinetic (PBPK) modeling for predicting drug-food interactions: An industry perspective. AAPS J  2020,22(6),123","journal-title":"AAPS J"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","volume":"108","author":"Grimstein M.","year":"2019","unstructured":"Grimstein M.; Yang Y.; Zhang X.; Grillo J.; Huang S.M.; Zineh I.; Wang Y.; Physiologically based pharmacokinetic modeling in regulatory science: An update from the U.S. Food and Drug Administration\u2019s office of clinical pharmacology. J Pharm Sci  2019,108(1),21-25","journal-title":"J Pharm Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.dmpk.2019.11.005","volume":"35","author":"Cole S.","year":"2020","unstructured":"Cole S.; Kerwash E.; Andersson A.; A summary of the current drug interaction guidance from the European Medicines Agency and considerations of future updates. Drug Metab Pharmacokinet  2020,35(1),2-11","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s11095-022-03274-2","volume":"39","author":"Lin W.","year":"2022","unstructured":"Lin W.; Chen Y.; Unadkat J.D.; Zhang X.; Wu D.; Heimbach T.; Applications, challenges, and outlook for PBPK modeling and simulation: A regulatory, industrial and academic perspective. Pharm Res  2022,39(8),1701-1731","journal-title":"Pharm Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/psp4.13013","volume":"12","author":"Abla N.","year":"2023","unstructured":"Abla N.; Howgate E.; Rowland-Yeo K.; Dickins M.; Bergagnini-Kolev M.C.; Chen K.F.; McFeely S.; Bonner J.J.; Santos L.G.A.; Gobeau N.; Burt H.; Barter Z.; Jones H.M.; Wesche D.; Charman S.A.; M\u00f6hrle J.J.; Burrows J.N.; Almond L.M.; Development and application of a PBPK modeling strategy to support antimalarial drug development. CPT Pharmacometrics Syst Pharmacol  2023,12(9),1335-1346","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s40495-020-00212-x","volume":"6","author":"Perry C.","year":"2020","unstructured":"Perry C.; Davis G.; Conner T.M.; Zhang T.; Utilization of physiologically based pharmacokinetic modeling in clinical pharmacology and therapeutics: An overview. Curr Pharmacol Rep  2020,6(3),71-84","journal-title":"Curr Pharmacol Rep"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/bdd.2208","volume":"40","author":"Wei L.","year":"2019","unstructured":"Wei L.; Mansoor N.; Khan R.A.; Czejka M.; Ahmad T.; Ahmed M.; Ali M.; Yang D.H.; WB\u2010PBPK approach in predicting zidovudine pharmacokinetics in preterm neonates. Biopharm Drug Dispos  2019,40(9),341-349","journal-title":"Biopharm Drug Dispos"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.ejps.2008.12.010","volume":"36","author":"von Kleist M.","year":"2009","unstructured":"von Kleist M.; Huisinga W.; Pharmacokinetic\u2013pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on zidovudine. Eur J Pharm Sci  2009,36(4-5),532-543","journal-title":"Eur J Pharm Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ijantimicag.2014.12.016","volume":"45","author":"Sy S.K.B.","year":"2015","unstructured":"Sy S.K.B.; Malmberg R.; Matsushima A.; Asin-Prieto E.; Rosenkranz B.; Cotton M.F.; Derendorf H.; Innes S.; Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. Int J Antimicrob Agents  2015,45(4),413-419","journal-title":"Int J Antimicrob Agents"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3390\/pharmaceutics14020406","volume":"14","author":"Zazo H.","year":"2022","unstructured":"Zazo H.; Colino C.I.; Guti\u00e9rrez-Mill\u00e1n C.; Cordero A.A.; Bartneck M.; Lanao J.M.; Physiologically based pharmacokinetic (PBPK) model of gold nanoparticle-based drug delivery system for stavudine biodistribution. Pharmaceutics  2022,14(2),406","journal-title":"Pharmaceutics"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.3390\/pharmaceutics15051424","volume":"15","author":"Jacobs T.G.","year":"2023","unstructured":"Jacobs T.G.; de Hoop-Sommen M.A.; Nieuwenstein T.; van der Heijden J.E.M.; de Wildt S.N.; Burger D.M.; Colbers A.; Freriksen J.J.M.; Lamivudine and emtricitabine dosing proposal for children with HIV and chronic kidney disease, supported by physiologically based pharmacokinetic modelling. Pharmaceutics  2023,15(5),1424","journal-title":"Pharmaceutics"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40262-021-01103-0","volume":"61","author":"Abduljalil K.","year":"2022","unstructured":"Abduljalil K.; Pansari A.; Ning J.; Jamei M.; Prediction of maternal and fetal acyclovir, emtricitabine, lamivudine, and metformin concentrations during pregnancy using a physiologically based pharmacokinetic modeling approach. Clin Pharmacokinet  2022,61(5),725-748","journal-title":"Clin Pharmacokinet"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1111\/bcp.12685","volume":"80","author":"De Sousa Mendes M.","year":"2015","unstructured":"De Sousa Mendes M.; Hirt D.; Urien S.; Valade E.; Bouazza N.; Foissac F.; Blanche S.; Treluyer J.M.; Benaboud S.; Physiologically\u2010based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women. Br J Clin Pharmacol  2015,80(5),1031-1041","journal-title":"Br J Clin Pharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40268-019-00285-0","volume":"19","author":"De Sousa Mendes M.","year":"2019","unstructured":"De Sousa Mendes M.; Chetty M.; Are standard doses of renally-excreted antiretrovirals in older patients appropriate: A PBPK study comparing exposures in the elderly population with those in renal impairment. Drugs R D  2019,19(4),339-350","journal-title":"Drugs R D"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"ofy225","DOI":"10.1093\/ofid\/ofy225","volume":"5","author":"Fischetti B.","year":"2018","unstructured":"Fischetti B.; Shah K.; Taft D.R.; Berkowitz L.; Bakshi A.; Cha A.; Real-world experience with higher-than-recommended doses of lamivudine in patients with varying degrees of renal impairment. Open Forum Infect Dis  2018,5(10),ofy225","journal-title":"Open Forum Infect Dis"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2174\/1570163816666190214164916","volume":"17","author":"Shah K.","year":"2020","unstructured":"Shah K.; Fischetti B.; Cha A.; Taft D.R.; Using PBPK modeling to predict drug exposure and support dosage adjustments in patients with renal impairment: An example with lamivudine. Curr Drug Discov Technol  2020,17(3),387-396","journal-title":"Curr Drug Discov Technol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1007\/s11095-023-03594-x","volume":"40","author":"Chang S.Y.","year":"2023","unstructured":"Chang S.Y.; Huang W.; Chapron A.; Qui\u00f1ones A.J.L.; Wang J.; Isoherranen N.; Shen D.D.; Kelly E.J.; Himmelfarb J.; Yeung C.K.; Incorporating uremic solute-mediated inhibition of OAT1\/3 improves PBPK prediction of tenofovir renal and systemic disposition in patients with severe kidney disease. Pharm Res  2023,40(11),2597-2606","journal-title":"Pharm Res"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2174\/1389200224666230130093314","volume":"23","author":"Zhang X.","year":"2022","unstructured":"Zhang X.; Luo T.; Yang H.; Ma W.Y.; He Q.; Xu M.; Yang Y.; Physiologically-based pharmacokinetic modeling of tenofovir disoproxil fumarate in pregnant women. Curr Drug Metab  2022,23(14),1115-1123","journal-title":"Curr Drug Metab"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bcp.12815","volume":"81","author":"De Sousa Mendes M.","year":"2016","unstructured":"De Sousa Mendes M.; Hirt D.; Vinot C.; Valade E.; Lui G.; Pressiat C.; Bouazza N.; Foissac F.; Blanche S.; L\u00ea M.P.; Peytavin G.; Treluyer J.M.; Urien S.; Benaboud S.; Prediction of human fetal pharmacokinetics using ex vivo human placenta perfusion studies and physiologically based models. Br J Clin Pharmacol  2016,81(4),646-657","journal-title":"Br J Clin Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1093\/jac\/dkab298","volume":"76","author":"Scholz E.M.B.","year":"2021","unstructured":"Scholz E.M.B.; Cao Y.; Kashuba A.D.M.; A cross-species comparison of antiretroviral penetration into lymph nodes using novel physiologically based pharmacokinetic models. J Antimicrob Chemother  2021,76(11),2890-2893","journal-title":"J Antimicrob Chemother"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"e00155","DOI":"10.1128\/AAC.00155-20","volume":"64","author":"Rajoli R.K.R.","year":"2020","unstructured":"Rajoli R.K.R.; Demkovich Z.R.; Flexner C.; Owen A.; Siccardi M.; Predicting pharmacokinetics of a tenofovir alafenamide subcutaneous implant using physiologically based pharmacokinetic modelling. Antimicrob Agents Chemother  2020,64(8),e00155-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"e00105","DOI":"10.1128\/AAC.00105-17","volume":"61","author":"Moss D.M.","year":"2017","unstructured":"Moss D.M.; Domanico P.; Watkins M.; Park S.; Randolph R.; Wring S.; Rajoli R.K.R.; Hobson J.; Rannard S.; Siccardi M.; Owen A.; Simulating intestinal transporter and enzyme activity in a physiologically based pharmacokinetic model for tenofovir disoproxil fumarate. Antimicrob Agents Chemother  2017,61(7),e00105-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40262-014-0227-1","volume":"54","author":"Rajoli R.K.R.","year":"2015","unstructured":"Rajoli R.K.R.; Back D.J.; Rannard S.; Freel Meyers C.L.; Flexner C.; Owen A.; Siccardi M.; Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin Pharmacokinet  2015,54(6),639-650","journal-title":"Clin Pharmacokinet"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40262-016-0445-9","volume":"56","author":"Duan P.","year":"2017","unstructured":"Duan P.; Fisher J.W.; Yoshida K.; Zhang L.; Burckart G.J.; Wang J.; Physiologically based pharmacokinetic prediction of linezolid and emtricitabine in neonates and infants. Clin Pharmacokinet  2017,56(4),383-394","journal-title":"Clin Pharmacokinet"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1002\/jcph.1845","volume":"61","author":"Liu X.I.","year":"2021","unstructured":"Liu X.I.; van den Anker J.N.; Burckart G.J.; Dallmann A.; Evaluation of physiologically based pharmacokinetic models to predict the absorption of BCS class I drugs in different pediatric age groups. J Clin Pharmacol  (Suppl. 1)2021,61(S1),S94-S107","journal-title":"J Clin Pharmacol"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"723006","DOI":"10.3389\/fped.2021.723006","volume":"9","author":"Liu X.I.","year":"2021","unstructured":"Liu X.I.; Green D.J.; van den Anker J.N.; Rakhmanina N.Y.; Ahmadzia H.K.; Momper J.D.; Park K.; Burckart G.J.; Dallmann A.; Mechanistic modeling of placental drug transfer in humans: How do differences in maternal\/fetal fraction of unbound drug and placental influx\/efflux transfer rates affect fetal pharmacokinetics? Front Pediatr  2021,9,723006","journal-title":"Front Pediatr"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/jcph.1515","volume":"60","author":"Liu X.I.","year":"2020","unstructured":"Liu X.I.; Momper J.D.; Rakhmanina N.; van den Anker J.N.; Green D.J.; Burckart G.J.; Best B.M.; Mirochnick M.; Capparelli E.V.; Dallmann A.; Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir. J Clin Pharmacol  2020,60(2),240-255","journal-title":"J Clin Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1208\/s12248-013-9505-3","volume":"15","author":"Xia B.","year":"2013","unstructured":"Xia B.; Heimbach T.; Gollen R.; Nanavati C.; He H.; A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy. AAPS J  2013,15(4),1012-1024","journal-title":"AAPS J"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s40262-016-0457-5","volume":"56","author":"De Sousa Mendes M.","year":"2017","unstructured":"De Sousa Mendes M.; Lui G.; Zheng Y.; Pressiat C.; Hirt D.; Valade E.; Bouazza N.; Foissac F.; Blanche S.; Treluyer J.M.; Urien S.; Benaboud S.; A physiologically-based pharmacokinetic model to predict human fetal exposure for a drug metabolized by several CYP450 pathways. Clin Pharmacokinet  2017,56(5),537-550","journal-title":"Clin Pharmacokinet"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/pharmaceutics16091163","volume":"16","author":"Costa B.","year":"2024","unstructured":"Costa B.; Gouveia M.J.; Vale N.; PBPK modeling of lamotrigine and efavirenz during pregnancy: Implications for personalized dosing and drug-drug interaction management. Pharmaceutics  2024,16(9),1163","journal-title":"Pharmaceutics"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3390\/pharmaceutics15102455","volume":"15","author":"Coppola P.","year":"2023","unstructured":"Coppola P.; Butler A.; Cole S.; Kerwash E.; Total and free blood and plasma concentration changes in pregnancy for medicines highly bound to plasma proteins: Application of physiologically based pharmacokinetic modelling to understand the impact on efficacy. Pharmaceutics  2023,15(10),2455","journal-title":"Pharmaceutics"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"734122","DOI":"10.3389\/fped.2021.734122","volume":"9","author":"Shenkoya B.","year":"2021","unstructured":"Shenkoya B.; Atoyebi S.; Eniayewu I.; Akinloye A.; Olagunju A.; Mechanistic modeling of maternal lymphoid and fetal plasma antiretroviral exposure during the third trimester. Front Pediatr  2021,9,734122","journal-title":"Front Pediatr"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/infdis\/jiy726","volume":"219","author":"Rajoli R.K.R.","year":"2019","unstructured":"Rajoli R.K.R.; Curley P.; Chiong J.; Back D.; Flexner C.; Owen A.; Siccardi M.; Predicting drug-drug interactions between rifampicin and long-acting cabotegravir and rilpivirine using physiologically based pharmacokinetic modeling. J Infect Dis  2019,219(11),1735-1742","journal-title":"J Infect Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/cpt.2912","volume":"114","author":"Pan X.","year":"2023","unstructured":"Pan X.; Rowland Yeo K.; Physiologically based pharmacokinetic modeling to determine the impact of CYP2B6 genotype on efavirenz exposure in children, mothers and breastfeeding infants. Clin Pharmacol Ther  2023,114(1),182-191","journal-title":"Clin Pharmacol Ther"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00228-020-02890-4","volume":"76","author":"Chetty M.","year":"2020","unstructured":"Chetty M.; Danckwerts M.P.; Julsing A.; Prediction of the exposure to a 400-mg daily dose of efavirenz in pregnancy: Is this dose adequate in extensive metabolisers of CYP2B6? Eur J Clin Pharmacol  2020,76(8),1143-1150","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3389\/fphar.2018.00247","volume":"9","author":"Chetty M.","year":"2018","unstructured":"Chetty M.; Cain T.; Wedagedera J.; Rostami-Hodjegan A.; Jamei M.; Application of physiologically based pharmacokinetic (PBPK) modeling within a bayesian framework to identify poor metabolizers of efavirenz (PM), using a test dose of efavirenz. Front Pharmacol  2018,9,247","journal-title":"Front Pharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"e01841","DOI":"10.1128\/AAC.01841-16","volume":"61","author":"Curley P.","year":"2017","unstructured":"Curley P.; Rajoli R.K.R.; Moss D.M.; Liptrott N.J.; Letendre S.; Owen A.; Siccardi M.; Efavirenz is predicted to accumulate in brain tissue: An in silico, in vitro, and in vivo investigation. Antimicrob Agents Chemother  2017,61(1),e01841-e16","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3851\/IMP2107","volume":"17","author":"De Roche M.","year":"2012","unstructured":"De Roche M.; Siccardi M.; Stoeckle M.; Livio F.; Back D.; Battegay M.; Marzolini C.; Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. Antivir Ther  2012,17(7),1381-1384","journal-title":"Antivir Ther"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jin2.21","volume":"1","author":"Siccardi M.","year":"2016","unstructured":"Siccardi M.; Martin P.; Smith D.; Curley P.; McDonald T.; Giardiello M.; Liptrott N.; Rannard S.; Owen A.; Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. J Interdiscip Nanomed  2016,1(3),110-123","journal-title":"J Interdiscip Nanomed"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/cid\/ciad495","volume":"78","author":"Berton M.","year":"2024","unstructured":"Berton M.; Bettonte S.; Stader F.; Decosterd L.; Tarr P.E.; Livio F.; Cavassini M.; Braun D.L.; Kusejko K.; Hachfeld A.; Bernasconi E.; Calmy A.; Schmid P.; Battegay M.; Marzolini C.; Abela I.; Aebi-Popp K.; Anagnostopoulos A.; Battegay M.; Bernasconi E.; Braun D.L.; Bucher H.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Fux C.; G\u00fcnthard H.; Hachfeld A.; Haerry D.; Hasse B.; Hirsch H.; Hoffmann M.; H\u00f6sli I.; Huber M.; Jackson-Perry D.; Kahlert C.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Kovari H.; Kusejko K.; Labhardt N.; Leuzinger K.; de Tejada B.M.; Marzolini C.; Metzner K.J.; M\u00fcller N.; Nemeth J.; Nicca D.; Notter J.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Salazar-Vizcaya L.; Schmid P.; Speck R.; St\u00f6ckle M.; Tarr P.; Trkola A.; Wandeler G.; Weisser M.; Yerly S.; Antiretroviral drug exposure and response in obese and morbidly obese people with human immunodeficiency virus (HIV): A study combining modelling and swiss HIV cohort data. Clin Infect Dis  2024,78(1),98-110","journal-title":"Clin Infect Dis"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"105297","DOI":"10.1016\/j.ejps.2020.105297","volume":"149","author":"Litou C.","year":"2020","unstructured":"Litou C.; Turner D.B.; Holmstock N.; Ceulemans J.; Box K.J.; Kostewicz E.; Kuentz M.; Holm R.; Dressman J.; Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state. Eur J Pharm Sci  2020,149,105297","journal-title":"Eur J Pharm Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"ofae171","DOI":"10.1093\/ofid\/ofae171","volume":"11","author":"Bettonte S.","year":"2024","unstructured":"Bettonte S.; Berton M.; Stader F.; Battegay M.; Marzolini C.; Drug exposure of long-acting cabotegravir and rilpivirine in older people with human immunodeficiency virus: A pharmacokinetic modeling study. Open Forum Infect Dis  2024,11(4),ofae171","journal-title":"Open Forum Infect Dis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/bcp.16006","volume":"91","author":"Atoyebi S.","year":"2025","unstructured":"Atoyebi S.; Bunglawala F.; Cottura N.; Gra\u00f1ana-Castillo S.; Montanha M.C.; Olagunju A.; Siccardi M.; Waitt C.; Physiologically\u2010based pharmacokinetic modelling of long\u2010acting injectable cabotegravir and rilpivirine in pregnancy. Br J Clin Pharmacol  2025,91(4),989-1002","journal-title":"Br J Clin Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/cid\/ciae060","volume":"79","author":"Bettonte S.","year":"2024","unstructured":"Bettonte S.; Berton M.; Stader F.; Battegay M.; Marzolini C.; Effect of obesity on the exposure of long-acting cabotegravir and rilpivirine: A modelling study. Clin Infect Dis  2024,79(2),477-486","journal-title":"Clin Infect Dis"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/cid\/ciac901","volume":"76","author":"Bettonte S.","year":"2023","unstructured":"Bettonte S.; Berton M.; Stader F.; Battegay M.; Marzolini C.; Management of drug-drug interactions between long-acting cabotegravir and rilpivirine and comedications with inducing properties: A modeling study. Clin Infect Dis  2023,76(7),1225-1236","journal-title":"Clin Infect Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1111\/bcp.15867","volume":"89","author":"Bettonte S.","year":"2023","unstructured":"Bettonte S.; Berton M.; Stader F.; Battegay M.; Marzolini C.; Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz\u2010containing regimen. Br J Clin Pharmacol  2023,89(12),3618-3628","journal-title":"Br J Clin Pharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1076266","DOI":"10.3389\/fphar.2022.1076266","volume":"13","author":"Gra\u00f1ana-Castillo S.","year":"2022","unstructured":"Gra\u00f1ana-Castillo S.; Montanha M.C.; Bearon R.; Khoo S.; Siccardi M.; Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling. Front Pharmacol  2022,13,1076266","journal-title":"Front Pharmacol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40262-017-0557-x","volume":"57","author":"Rajoli R.K.R.","year":"2018","unstructured":"Rajoli R.K.R.; Back D.J.; Rannard S.; Meyers C.F.; Flexner C.; Owen A.; Siccardi M.; In silico dose prediction for long-acting rilpivirine and cabotegravir administration to children and adolescents. Clin Pharmacokinet  2018,57(2),255-266","journal-title":"Clin Pharmacokinet"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejpb.2019.09.011","volume":"144","author":"Rajoli R.K.R.","year":"2019","unstructured":"Rajoli R.K.R.; Flexner C.; Chiong J.; Owen A.; Donnelly R.F.; Larra\u00f1eta E.; Siccardi M.; Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. Eur J Pharm Biopharm  2019,144,101-109","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40262-022-01127-0","volume":"61","author":"Bukkems V.E.","year":"2022","unstructured":"Bukkems V.E.; van Hove H.; Roelofsen D.; Freriksen J.J.M.; van Ewijk-Beneken Kolmer E.W.J.; Burger D.M.; van Drongelen J.; Svensson E.M.; Greupink R.; Colbers A.; Prediction of maternal and fetal doravirine exposure by integrating physiologically based pharmacokinetic modeling and human placenta perfusion experiments. Clin Pharmacokinet  2022,61(8),1129-1141","journal-title":"Clin Pharmacokinet"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jcph.1747","volume":"61","author":"Yee K.L.","year":"2021","unstructured":"Yee K.L.; Cabalu T.D.; Kuo Y.; Fillgrove K.L.; Liu Y.; Triantafyllou I.; McClain S.; Dreyer D.; Wenning L.; Stoch S.A.; Iwamoto M.; Sanchez R.I.; Khalilieh S.G.; Physiologically based pharmacokinetic modeling of doravirine and its major metabolite to support dose adjustment with rifabutin. J Clin Pharmacol  2021,61(3),394-405","journal-title":"J Clin Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1021\/acs.molpharmaceut.0c00043","volume":"17","author":"Arora S.","year":"2020","unstructured":"Arora S.; Pansari A.; Kilford P.; Jamei M.; Gardner I.; Turner D.B.; Biopharmaceutic in vitro in vivo extrapolation (IVIV_E) informed physiologically-based pharmacokinetic model of ritonavir norvir tablet absorption in humans under fasted and fed state conditions. Mol Pharm  2020,17(7),2329-2344","journal-title":"Mol Pharm"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s40262-015-0325-8","volume":"55","author":"Colbers A.","year":"2016","unstructured":"Colbers A.; Greupink R.; Litjens C.; Burger D.; Russel F.G.M.; Physiologically based modelling of darunavir\/ritonavir pharmacokinetics during pregnancy. Clin Pharmacokinet  2016,55(3),381-396","journal-title":"Clin Pharmacokinet"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ejpb.2011.04.005","volume":"79","author":"Shono Y.","year":"2011","unstructured":"Shono Y.; Jantratid E.; Dressman J.B.; Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: Case example nelfinavir. Eur J Pharm Biopharm  2011,79(2),349-356","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/phar.2703","volume":"43","author":"Salerno S.N.","year":"2023","unstructured":"Salerno S.N.; Capparelli E.V.; McIlleron H.; Gerhart J.G.; Dumond J.B.; Kashuba A.D.M.; Denti P.; Gonzalez D.; Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir\/ritonavir with rifampin in pediatric patients. Pharmacotherapy  2023,43(7),638-649","journal-title":"Pharmacotherapy"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1002\/jcph.936","volume":"57","author":"Wagner C.","year":"2017","unstructured":"Wagner C.; Zhao P.; Arya V.; Mullick C.; Struble K.; Au S.; Physiologically based pharmacokinetic modeling for predicting the effect of intrinsic and extrinsic factors on darunavir or lopinavir exposure coadministered with ritonavir. J Clin Pharmacol  2017,57(10),1295-1304","journal-title":"J Clin Pharmacol"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/psp4.13268","volume":"13","author":"Atoyebi S.","year":"2024","unstructured":"Atoyebi S.; Montanha M.C.; Nakijoba R.; Orrell C.; Mugerwa H.; Siccardi M.; Denti P.; Waitt C.; Physiologically based pharmacokinetic modeling of drug\u2013drug interactions between ritonavir\u2010boosted atazanavir and rifampicin in pregnancy. CPT Pharmacometrics Syst Pharmacol  2024,13(11),1967-1977","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40262-021-01067-1","volume":"61","author":"Montanha M.C.","year":"2022","unstructured":"Montanha M.C.; Fabrega F.; Howarth A.; Cottura N.; Kinvig H.; Bunglawala F.; Lloyd A.; Denti P.; Waitt C.; Siccardi M.; Predicting drug-drug interactions between rifampicin and ritonavir-boosted atazanavir using PBPK modelling. Clin Pharmacokinet  2022,61(3),375-386","journal-title":"Clin Pharmacokinet"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ejpb.2015.03.031","volume":"93","author":"Berlin M.","year":"2015","unstructured":"Berlin M.; Ruff A.; Kesisoglou F.; Xu W.; Wang M.H.; Dressman J.B.; Advances and challenges in PBPK modeling \u2013 Analysis of factors contributing to the oral absorption of atazanavir, a poorly soluble weak base. Eur J Pharm Biopharm  2015,93,267-280","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/psp4.12541","volume":"9","author":"Dong Z.","year":"2020","unstructured":"Dong Z.; Li J.; Wu F.; Zhao P.; Lee S.C.; Zhang L.; Seo P.; Zhang L.; Application of physiologically-based pharmacokinetic modeling to predict gastric pH-dependent drug-drug interactions for weak base drugs. CPT Pharmacometrics Syst Pharmacol  2020,9(8),456-465","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-017-0583-8","volume":"57","author":"Schalkwijk S.","year":"2018","unstructured":"Schalkwijk S.; Buaben A.O.; Freriksen J.J.M.; Colbers A.P.; Burger D.M.; Greupink R.; Russel F.G.M.; Prediction of fetal darunavir exposure by integrating human ex-vivo placental transfer and physiologically based pharmacokinetic modeling. Clin Pharmacokinet  2018,57(6),705-716","journal-title":"Clin Pharmacokinet"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.xphs.2021.09.037","volume":"111","author":"Segregur D.","year":"2022","unstructured":"Segregur D.; Mann J.; Moir A.; Karlsson E.M.; Dressman J.; Biorelevant in vitro tools and in silico modeling to assess pH-dependent drug-drug interactions for salts of weak acids: Case example potassium raltegravir. J Pharm Sci  2022,111(2),517-528","journal-title":"J Pharm Sci"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"106309","DOI":"10.1016\/j.ejps.2022.106309","volume":"179","author":"Moreira F.L.","year":"2022","unstructured":"Moreira F.L.; Tarozzo M.M.B.; Nardotto G.H.B.; Gon\u00e7alves J.C.S.; Schmidt S.; de-Moraes N.V.; Assessing the contribution of UGT isoforms on raltegravir drug disposition through PBPK modeling. Eur J Pharm Sci  2022,179,106309","journal-title":"Eur J Pharm Sci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1093\/jac\/dkt084","volume":"68","author":"Moss D.M.","year":"2013","unstructured":"Moss D.M.; Siccardi M.; Back D.J.; Owen A.; Predicting intestinal absorption of raltegravir using a population-based ADME simulation. J Antimicrob Chemother  2013,68(7),1627-1634","journal-title":"J Antimicrob Chemother"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/psp4.13251","volume":"13","author":"Ning J.","year":"2024","unstructured":"Ning J.; Pansari A.; Rowland Yeo K.; Heikkinen A.T.; Waitt C.; Almond L.M.; Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women. CPT Pharmacometrics Syst Pharmacol  2024,13(11),1924-1938","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/cpt.1748","volume":"107","author":"Freriksen J.J.M.","year":"2020","unstructured":"Freriksen J.J.M.; Schalkwijk S.; Colbers A.P.; Abduljalil K.; Russel F.G.M.; Burger D.M.; Greupink R.; Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling. Clin Pharmacol Ther  2020,107(6),1352-1361","journal-title":"Clin Pharmacol Ther"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1002\/jcph.2225","volume":"63","author":"Dallmann A.","year":"2023","unstructured":"Dallmann A.; van den Anker J.; Ahmadzia H.K.; Rakhmanina N.; Mechanistic modeling of the drug-drug interaction between efavirenz and dolutegravir: Is this interaction clinically relevant when switching from efavirenz to dolutegravir during pregnancy? J Clin Pharmacol  (Suppl. 1)2023,63(S1),S81-S95","journal-title":"J Clin Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"ofad361","DOI":"10.1093\/ofid\/ofad361","volume":"10","author":"Berton M.","year":"2023","unstructured":"Berton M.; Bettonte S.; Stader F.; Battegay M.; Marzolini C.; Impact of obesity on the drug-drug interaction between dolutegravir and rifampicin or any other strong inducers. Open Forum Infect Dis  2023,10(7),ofad361","journal-title":"Open Forum Infect Dis"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1093\/jac\/dkz506","volume":"75","author":"Bunglawala F.","year":"2020","unstructured":"Bunglawala F.; Rajoli R.K.R.; Mirochnick M.; Owen A.; Siccardi M.; Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. J Antimicrob Chemother  2020,75(3),640-647","journal-title":"J Antimicrob Chemother"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/cpt.2178","volume":"109","author":"Stader F.","year":"2021","unstructured":"Stader F.; Courlet P.; Decosterd L.A.; Battegay M.; Marzolini C.; Physiologically-based pharmacokinetic modeling combined with swiss HIV cohort study data supports no dose adjustment of bictegravir in elderly individuals living with HIV. Clin Pharmacol Ther  2021,109(4),1025-1029","journal-title":"Clin Pharmacol Ther"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/cpt.2221","volume":"110","author":"Stader F.","year":"2021","unstructured":"Stader F.; Battegay M.; Marzolini C.; Physiologically-based pharmacokinetic modeling to support the clinical management of drug-drug interactions with bictegravir. Clin Pharmacol Ther  2021,110(5),1231-1239","journal-title":"Clin Pharmacol Ther"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.3390\/pharmaceutics15122709","volume":"15","author":"Kinvig H.","year":"2023","unstructured":"Kinvig H.; Rajoli R.K.R.; Pertinez H.; Vora L.K.; Volpe-Zanutto F.; Donnelly R.F.; Rannard S.; Flexner C.; Siccardi M.; Owen A.; Physiologically based pharmacokinetic modelling of cabotegravir microarray patches in rats and humans. Pharmaceutics  2023,15(12),2709","journal-title":"Pharmaceutics"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1124\/dmd.118.085241","volume":"47","author":"Kimoto E.","year":"2019","unstructured":"Kimoto E.; Vourvahis M.; Scialis R.J.; Eng H.; Rodrigues A.D.; Varma M.V.S.; Mechanistic evaluation of the complex drug-drug interactions of maraviroc: Contribution of cytochrome P450 3A, P-glycoprotein and organic anion transporting polypeptide 1B1. Drug Metab Dispos  2019,47(5),493-503","journal-title":"Drug Metab Dispos"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2125.2008.03198.x","volume":"66","author":"Hyland R.","year":"2008","unstructured":"Hyland R.; Dickins M.; Collins C.; Jones H.; Jones B.; Maraviroc: in vitro assessment of drug\u2013drug interaction potential. Br J Clin Pharmacol  2008,66(4),498-507","journal-title":"Br J Clin Pharmacol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1002\/psp4.13156","volume":"13","author":"Salem F.","year":"2024","unstructured":"Salem F.; Nguyen D.; Bush M.; Moore K.P.; Mudunuru J.; Stamatopoulos K.; Thakkar N.; Taskar K.S.; Development of a physiologically based pharmacokinetic model of fostemsavir and its pivotal application to support dosing in pregnancy. CPT Pharmacometrics Syst Pharmacol  2024,13(11),1881-1892","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"e1238","DOI":"10.1002\/prp2.1238","volume":"12","author":"Nguyen D.","year":"2024","unstructured":"Nguyen D.; Miao X.; Taskar K.; Magee M.; Gorycki P.; Moore K.; Tai G.; No dose adjustment of metformin or substrates of organic cation transporters (OCT)1 and OCT2 and multidrug and toxin extrusion protein (MATE)1\/2K with fostemsavir coadministration based on modeling approaches. Pharmacol Res Perspect  2024,12(4),e1238","journal-title":"Pharmacol Res Perspect"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1208\/s12248-020-00460-1","volume":"22","author":"Pan X.","year":"2020","unstructured":"Pan X.; Stader F.; Abduljalil K.; Gill K.L.; Johnson T.N.; Gardner I.; Jamei M.; Development and application of a physiologically-based pharmacokinetic model to predict the pharmacokinetics of therapeutic proteins from full-term neonates to adolescents. AAPS J  2020,22(4),76","journal-title":"AAPS J"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10928-020-09698-w","volume":"47","author":"Abduljalil K.","year":"2020","unstructured":"Abduljalil K.; Badhan R.K.S.; Drug dosing during pregnancy\u2014opportunities for physiologically based pharmacokinetic models. J Pharmacokinet Pharmacodyn  2020,47(4),319-340","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/fcp.12967","volume":"38","author":"Berezowska M.","year":"2024","unstructured":"Berezowska M.; Sharma P.; Pilla Reddy V.; Coppola P.; Physiologically Based Pharmacokinetic modelling of drugs in pregnancy: A mini\u2010review on availability and limitations. Fundam Clin Pharmacol  2024,38(3),402-409","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40262-019-00806-9","volume":"58","author":"Boyle A.","year":"2019","unstructured":"Boyle A.; Hodge D.; Marzolini C.; Khoo S.; Clinical pharmacodynamics, pharmacokinetics, and drug interaction profile of doravirine. Clin Pharmacokinet  2019,58(12),1553-1565","journal-title":"Clin Pharmacokinet"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/00498254.2016.1158886","volume":"47","author":"Reznicek J.","year":"2017","unstructured":"Reznicek J.; Ceckova M.; Cerveny L.; M\u00fcller F.; Staud F.; Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters. Xenobiotica  2017,47(1),77-85","journal-title":"Xenobiotica"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"e02168","DOI":"10.1128\/AAC.02168-20","volume":"65","author":"Eke A.C.","year":"2021","unstructured":"Eke A.C.; Shoji K.; Best B.M.; Momper J.D.; Stek A.M.; Cressey T.R.; Mirochnick M.; Capparelli E.V.; Population pharmacokinetics of tenofovir in pregnant and postpartum women using tenofovir disoproxil fumarate. Antimicrob Agents Chemother  2021,65(3),e02168-20","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2990","DOI":"10.1093\/jac\/dkae319","volume":"79","author":"Tsirizani L.","year":"2024","unstructured":"Tsirizani L.; Mohsenian Naghani S.; Waalewijn H.; Szubert A.; Mulenga V.; Chabala C.; Bwakura-Dangarembizi M.; Chitsamatanga M.; Rutebarika D.A.; Musiime V.; Kasozi M.; Lugemwa A.; Monkiewicz L.N.; McIlleron H.M.; Burger D.M.; Gibb D.M.; Denti P.; Wasmann R.E.; Colbers A.; Pharmacokinetics of once-daily darunavir\/ritonavir in second-line treatment in African children with HIV. J Antimicrob Chemother  2024,79(11),2990-2998","journal-title":"J Antimicrob Chemother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1517\/17425255.2015.1108963","volume":"11","author":"Enioutina E.Y.","year":"2015","unstructured":"Enioutina E.Y.; Constance J.E.; Stockmann C.; Linakis M.W.; Yu T.; Rower J.E.; Balch A.H.; Sherwin C.M.; Pharmacokinetic considerations in the use of antivirals in neonates. Expert Opin Drug Metab Toxicol  2015,11(12),1861-1878","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.3390\/pharmaceutics15122765","volume":"15","author":"Zhang W.","year":"2023","unstructured":"Zhang W.; Zhang Q.; Cao Z.; Zheng L.; Hu W.; Physiologically based pharmacokinetic modeling in neonates: Current status and future perspectives. Pharmaceutics  2023,15(12),2765","journal-title":"Pharmaceutics"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/cpdd.1335","volume":"13","author":"Huang X.","year":"2024","unstructured":"Huang X.; Wang G.; Huang J.; Liang W.; Guan H.; Liu H.; Deng Y.; You Y.; Zhang B.; Bioequivalence and pharmacokinetics study of two zidovudine\/lamivudine tablets in Chinese healthy volunteers. Clin Pharmacol Drug Dev  2024,13(1),14-20","journal-title":"Clin Pharmacol Drug Dev"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/17512433.2018.1393331","volume":"11","author":"Clarke D.F.","year":"2018","unstructured":"Clarke D.F.; Penazzato M.; Capparelli E.; Cressey T.R.; Siberry G.; Sugandhi N.; Mirochnick M.; Group W.H.O.P.A.W.; Prevention and treatment of HIV infection in neonates: Evidence base for existing WHO dosing recommendations and implementation considerations. Expert Rev Clin Pharmacol  2018,11(1),83-93","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","volume":"32","author":"Mulligan N.","year":"2018","unstructured":"Mulligan N.; Best B.M.; Wang J.; Capparelli E.V.; Stek A.; Barr E.; Buschur S.L.; Acosta E.P.; Smith E.; Chakhtoura N.; Burchett S.; Mirochnick M.; Team I.P.P.; Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV. AIDS  2018,32(6),729-737","journal-title":"AIDS"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40262-019-00822-9","volume":"59","author":"Stader F.","year":"2020","unstructured":"Stader F.; Kinvig H.; Penny M.A.; Battegay M.; Siccardi M.; Marzolini C.; Physiologically based pharmacokinetic modelling to identify pharmacokinetic parameters driving drug exposure changes in the elderly. Clin Pharmacokinet  2020,59(3),383-401","journal-title":"Clin Pharmacokinet"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40262-016-0422-3","volume":"55","author":"Schlender J.F.","year":"2016","unstructured":"Schlender J.F.; Meyer M.; Thelen K.; Krauss M.; Willmann S.; Eissing T.; Jaehde U.; Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals. Clin Pharmacokinet  2016,55(12),1573-1589","journal-title":"Clin Pharmacokinet"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2174\/1389200224666230509104404","volume":"24","author":"Wu X.","year":"2023","unstructured":"Wu X.; Sia J.E.V.; Hai M.; Lai X.; Li H.; Cui C.; Liu D.; Physiologically based pharmacokinetic model for older adults and its application in geriatric drug research. Curr Drug Metab  2023,24(3),211-222","journal-title":"Curr Drug Metab"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1093\/jac\/dkad103","volume":"78","author":"Thoueille P.","year":"2023","unstructured":"Thoueille P.; Alves Saldanha S.; Desfontaine V.; Kusejko K.; Courlet P.; Andre P.; Cavassini M.; Decosterd L.A.; Buclin T.; Guidi M.; Swiss H.I.V.C.S.; Population pharmacokinetic modelling to characterize the effect of chronic kidney disease on tenofovir exposure after tenofovir alafenamide administration. J Antimicrob Chemother  2023,78(6),1433-1443","journal-title":"J Antimicrob Chemother"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1358\/dot.2019.55.11.3068796","volume":"55","author":"Zeuli J.","year":"2019","unstructured":"Zeuli J.; Rizza S.; Bhatia R.; Temesgen Z.; Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc)  2019,55(11),669-682","journal-title":"Drugs Today (Barc)"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.clinthera.2022.09.009","volume":"44","author":"Yu J.","year":"2022","unstructured":"Yu J.; Wang Y.; Ragueneau-Majlessi I.; Strong pharmacokinetic drug-drug interactions with drugs approved by the US Food and Drug Administration in 2021: Mechanisms and clinical implications. Clin Ther  2022,44(11),1536-1544","journal-title":"Clin Ther"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"100021","DOI":"10.1124\/dmd.123.001384","volume":"53","author":"Foti R.S.","year":"2024","unstructured":"Foti R.S.; Utility of PBPK modeling in predicting and characterizing clinical drug interactions. Drug Metab Dispos  2024,53(1),100021","journal-title":"Drug Metab Dispos"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1186\/s12879-024-09958-x","volume":"24","author":"Heydari M.","year":"2024","unstructured":"Heydari M.; Foroozanfar Z.; Bazmi S.; Mohammadi Z.; Joulaei H.; Ansari G.; The prevalence of antiretroviral drug interactions with other drugs used in women living with HIV and its association with HIV drug change and patient compliance. BMC Infect Dis  2024,24(1),1123","journal-title":"BMC Infect Dis"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/jcph.6142","volume":"65","author":"Ridge S.","year":"2025","unstructured":"Ridge S.; Yang X.; Madabushi R.; Ramamoorthy A.; Addressing drug-drug interaction knowledge gaps at the time of approval: An analysis of FDA postmarketing requirements and commitments from 2009 to 2023. J Clin Pharmacol  2025,65(3),378-388","journal-title":"J Clin Pharmacol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"106838","DOI":"10.1016\/j.ejps.2024.106838","volume":"200","author":"Sun Z.","year":"2024","unstructured":"Sun Z.; Zhao N.; Zhao X.; Wang Z.; Liu Z.; Cui Y.; Application of physiologically based pharmacokinetic modeling of novel drugs approved by the U.S. food and drug administration. Eur J Pharm Sci  2024,200,106838","journal-title":"Eur J Pharm Sci"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1007\/s12272-017-0976-0","volume":"40","author":"Min J.S.","year":"2017","unstructured":"Min J.S.; Bae S.K.; Prediction of drug\u2013drug interaction potential using physiologically based pharmacokinetic modeling. Arch Pharm Res  2017,40(12),1356-1379","journal-title":"Arch Pharm Res"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/00498254.2018.1451667","volume":"49","author":"Sanchez R.I.","year":"2019","unstructured":"Sanchez R.I.; Fillgrove K.L.; Yee K.L.; Liang Y.; Lu B.; Tatavarti A.; Liu R.; Anderson M.S.; Behm M.O.; Fan L.; Li Y.; Butterton J.R.; Iwamoto M.; Khalilieh S.G.; Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica  2019,49(4),422-432","journal-title":"Xenobiotica"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/jcph.1103","volume":"58","author":"Khalilieh S.G.","year":"2018","unstructured":"Khalilieh S.G.; Yee K.L.; Sanchez R.I.; Liu R.; Fan L.; Martell M.; Jordan H.; Iwamoto M.; Multiple doses of rifabutin reduce exposure of doravirine in healthy subjects. J Clin Pharmacol  2018,58(8),1044-1052","journal-title":"J Clin Pharmacol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-021-01005-1","volume":"60","author":"Hodge D.","year":"2021","unstructured":"Hodge D.; Back D.J.; Gibbons S.; Khoo S.H.; Marzolini C.; Pharmacokinetics and drug-drug interactions of long-acting intramuscular cabotegravir and rilpivirine. Clin Pharmacokinet  2021,60(7),835-853","journal-title":"Clin Pharmacokinet"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1007\/s11095-012-0942-y","volume":"30","author":"Kis O.","year":"2013","unstructured":"Kis O.; Zastre J.A.; Hoque M.T.; Walmsley S.L.; Bendayan R.; Role of drug efflux and uptake transporters in atazanavir intestinal permeability and drug-drug interactions. Pharm Res  2013,30(4),1050-1064","journal-title":"Pharm Res"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1124\/dmd.119.087684","volume":"47","author":"Tupova L.","year":"2019","unstructured":"Tupova L.; Ceckova M.; Ambrus C.; Sorf A.; Ptackova Z.; Gaborik Z.; Staud F.; Interactions between maraviroc and the ABCB1, ABCG2, and ABCC2 transporters: An important role in transplacental pharmacokinetics. Drug Metab Dispos  2019,47(9),954-960","journal-title":"Drug Metab Dispos"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/QAI.0000000000000090","volume":"65","author":"Vourvahis M.","year":"2014","unstructured":"Vourvahis M.; Plotka A.; Kantaridis C.; Fang A.; Heera J.; The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: An open-label, fixed-sequence study in healthy volunteers. J Acquir Immune Defic Syndr  2014,65(5),564-570","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cpt.3188","volume":"116","author":"Viviani R.","year":"2024","unstructured":"Viviani R.; Berres J.; Stingl J.C.; Phenotypic models of drug-drug-gene interactions mediated by cytochrome drug-metabolizing enzymes. Clin Pharmacol Ther  2024,116(3),592-601","journal-title":"Clin Pharmacol Ther"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"940661","DOI":"10.3389\/fgene.2022.940661","volume":"13","author":"Zondo N.M.","year":"2022","unstructured":"Zondo N.M.; Sobia P.; Sivro A.; Ngcapu S.; Ramsuran V.; Archary D.; Pharmacogenomics of drug transporters for antiretroviral long-acting pre-exposure prophylaxis for HIV. Front Genet  2022,13,940661","journal-title":"Front Genet"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/dmd.119.086348","volume":"47","author":"Wang P.F.","year":"2019","unstructured":"Wang P.F.; Neiner A.; Kharasch E.D.; Efavirenz metabolism: Influence of polymorphic CYP2B6 variants and stereochemistry. Drug Metab Dispos  2019,47(10),1195-1205","journal-title":"Drug Metab Dispos"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/phar.1852","volume":"36","author":"Vo T.T.","year":"2016","unstructured":"Vo T.T.; Varghese Gupta S.; Role of cytochrome P450 2B6 pharmacogenomics in determining efavirenz-mediated central nervous system toxicity, treatment outcomes, and dosage adjustments in patients with human immunodeficiency virus infection. Pharmacotherapy  2016,36(12),1245-1254","journal-title":"Pharmacotherapy"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/jac\/dkr498","volume":"67","author":"Cattaneo D.","year":"2012","unstructured":"Cattaneo D.; Gervasoni C.; Meraviglia P.; Landonio S.; Fucile S.; Cozzi V.; Baldelli S.; Pellegrini M.; Galli M.; Clementi E.; Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. J Antimicrob Chemother  2012,67(2),460-464","journal-title":"J Antimicrob Chemother"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/s41598-018-25803-z","volume":"8","author":"Belkhir L.","year":"2018","unstructured":"Belkhir L.; Seguin-Devaux C.; Elens L.; Pauly C.; Gengler N.; Schneider S.; Ruelle J.; Haufroid V.; Vandercam B.; Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Sci Rep  2018,8(1),7359","journal-title":"Sci Rep"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.kint.2022.06.021","volume":"102","author":"Lucas A.","year":"2022","unstructured":"Lucas A.; Wyatt C.M.; HIV at 40: Kidney disease in HIV treatment, prevention, and cure. Kidney Int  2022,102(4),740-749","journal-title":"Kidney Int"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/QAD.0000000000003153","volume":"36","author":"Drak D.","year":"2022","unstructured":"Drak D.; Shamu T.; Heron J.E.; Chimbetete C.; Dahwa R.; Gracey D.M.; Renal function and associated mortality risk in adults commencing HIV antiretroviral therapy in Zimbabwe. AIDS  2022,36(5),631-636","journal-title":"AIDS"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1002\/jcph.1713","volume":"60","author":"Malik P.R.V.","year":"2020","unstructured":"Malik P.R.V.; Yeung C.H.T.; Ismaeil S.; Advani U.; Djie S.; Edginton A.N.; A physiological approach to pharmacokinetics in chronic kidney disease. J Clin Pharmacol  (Suppl. 1)2020,60,S52-S62","journal-title":"J Clin Pharmacol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.3390\/pharmaceutics15071922","volume":"15","author":"Rowland Yeo K.","year":"2023","unstructured":"Rowland Yeo K.; Hatley O.; Small B.G.; Johnson T.N.; Physiologically based pharmacokinetic modelling to predict imatinib exposures in cancer patients with renal dysfunction: A case study. Pharmaceutics  2023,15(7),1922","journal-title":"Pharmaceutics"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/17425255.2024.2311154","volume":"20","author":"Zamir A.","year":"2024","unstructured":"Zamir A.; Alqahtani F.; Rasool M.F.; Chronic kidney disease and physiologically based pharmacokinetic modeling: A critical review of existing models. Expert Opin Drug Metab Toxicol  2024,20(1-2),95-105","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/17425255.2019.1577821","volume":"15","author":"Cattaneo D.","year":"2019","unstructured":"Cattaneo D.; Capetti A.; Rizzardini G.; Drug\u2013drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment. Expert Opin Drug Metab Toxicol  2019,15(3),245-252","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","volume":"17","author":"Bailin S.S.","year":"2020","unstructured":"Bailin S.S.; Gabriel C.L.; Wanjalla C.N.; Koethe J.R.; Obesity and weight gain in persons with HIV. Curr HIV\/AIDS Rep  2020,17(2),138-150","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1093\/jac\/dkac368","volume":"77","author":"Zino L.","year":"2022","unstructured":"Zino L.; Stalenhoef J.; Colbers A.; Burger D.M.; Outcomes of modern antiretroviral therapy in obese individuals living with HIV. J Antimicrob Chemother  2022,77(12),3215-3220","journal-title":"J Antimicrob Chemother"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"107200","DOI":"10.1016\/j.ijantimicag.2024.107200","volume":"64","author":"De Nicol\u00f2 A.","year":"2024","unstructured":"De Nicol\u00f2 A.; Palermiti A.; Dispinseri S.; Marchetti G.; Trunfio M.; De Vivo E.; D\u2019Avolio A.; Muscatello A.; Gori A.; Rusconi S.; Bruzzesi E.; Gabrieli A.; Bernasconi D.P.; Bandera A.; Nozza S.; Calcagno A.; Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study. Int J Antimicrob Agents  2024,64(2),107200","journal-title":"Int J Antimicrob Agents"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"123574","DOI":"10.1016\/j.ijpharm.2023.123574","volume":"648","author":"Wong A.","year":"2023","unstructured":"Wong A.; Chu Y.; Chen H.; Feng W.; Ji L.; Qin C.; Stocks M.J.; Marlow M.; Gershkovich P.; Distribution of lamivudine into lymph node HIV reservoir. Int J Pharm  2023,648,123574","journal-title":"Int J Pharm"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.2217\/pgs.13.111","volume":"14","author":"S\u00e1nchez Mart\u00edn A.","year":"2013","unstructured":"S\u00e1nchez Mart\u00edn A.; Cabrera Figueroa S.; Cruz Guerrero R.; Hurtado L.P.; Hurl\u00e9 A.D.G.; Carracedo \u00c1lvarez \u00c1.; Impact of pharmacogenetics on CNS side effects related to efavirenz. Pharmacogenomics  2013,14(10),1167-1178","journal-title":"Pharmacogenomics"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/hiv.13600","volume":"25","author":"Ranzani A.","year":"2024","unstructured":"Ranzani A.; Castelli F.; Di Biagio A.; d\u2019Arminio Monforte A.; D\u2019Avolio A.; Soria A.; Bai F.; Foc\u00e0 E.; Taramasso L.; Calcagno A.; Bresciani E.; Torsello A.; Bonfanti P.; Lapadula G.; Influence of efavirenz and 8\u2010hydroxy\u2010efavirenz plasma levels on cognition and central nervous system side effects. HIV Med  2024,25(4),491-497","journal-title":"HIV Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/17425255.2020.1754792","volume":"16","author":"Neary M.","year":"2020","unstructured":"Neary M.; Owen A.; Olagunju A.; Pharmacokinetics of HIV therapies in pregnant patients: An update. Expert Opin Drug Metab Toxicol  2020,16(6),449-461","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"100013","DOI":"10.1124\/dmd.123.000960","volume":"53","author":"Isoherranen N.","year":"2025","unstructured":"Isoherranen N.; Physiologically based pharmacokinetic modeling of small molecules: How much progress have we made? Drug Metab Dispos  2025,53(1),100013","journal-title":"Drug Metab Dispos"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002392579250902053006","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/245367\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892002392579250902053006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T15:15:24Z","timestamp":1768230924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/245367\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":137,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892002392579250902053006","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-26","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}